Dexamethasone

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Post-Surgical Ocular Pain

Conditions

Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation

Trial Timeline

Apr 1, 2014 → Mar 1, 2015

NCT ID

NCT02089113

About Dexamethasone

Dexamethasone is a phase 3 stage product being developed by Ocular Therapeutix for Post-Surgical Ocular Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02089113. Target conditions include Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04205916	Approved	Recruiting	Nov 4, 2019	Dec 1, 2020	Patient Preference
NCT02736175	Phase 3	Completed	Oct 1, 2015	Jul 1, 2016	Post-Surgical Ocular Pain
NCT02988882	Phase 3	Completed	Jun 1, 2015	Apr 27, 2016	Chronic Allergic Conjunctivitis
NCT02445326	Phase 3	Completed	Apr 1, 2015	Sep 1, 2015	Chronic Allergic Conjunctivitis
NCT02468700	Phase 2	Completed	Jan 1, 2015	Nov 1, 2015	Dry Eye
NCT02089113	Phase 3	Completed	Apr 1, 2014	Mar 1, 2015	Post-Surgical Ocular Pain
NCT02062905	Phase 2	Completed	Mar 1, 2014	Nov 1, 2014	Chronic Allergic Conjunctivitis

Competing Products

5 competing products in Post-Surgical Ocular Pain

See all competitors

Product	Company	Stage	Hype Score
Celecoxib	Astellas Pharma	Pre-clinical	23
Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + Placebo	Pfizer	Phase 3	76
valdecoxib + valdecoxib/placebo + placebo	Pfizer	Phase 3	76
PF-04531083 + PF-04531083 + Ibuprofen	Pfizer	Phase 2	51
Dexamethasone	Ocular Therapeutix	Phase 3	72

Other Products from Ocular Therapeutix

Dextenza + Prednisolone AcetateApproved

Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal PulsationApproved

Dextenza 0.4Mg Ophthalmic Insert + Prednisolone AcetateApproved

Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%Approved

Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Approved